PHASE II STUDY OF 2-CHLORODEOXYADENOSINE (2CDA) FOLLOWED BY RITUXIMAB IN HAIRY CELL LEUKEMIA
The goal of this clinical research study is to learn if treatment with 2CDA (cladribine) followed by treatment with rituximab can help to control HCL. The safety of this combination treatment will also be studied.
Disease Group: Leukemia
Treatment Agent: 2-Chlorodeoxyadenosine, Rituximab
Treatment Location: Only at MD Anderson
Estimatated Length of Stay in Houston: No hospitalization required.
Return Visit: Daily for 5 days, then weekly for 8 weeks then every three months for first year. Patients can receive their treatment locally after the first dose of both agents has been administered at M.D. Anderson.
Home Care: Patients can receive their 2CDA and Rituximab treatment locally after the first ;dose of both agents has been administered at M.D. Anderson.
IRB Review and Approval Date: MAY 19,2004
Recruitment Status: Open
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: